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Abstract: In 1934, Epstein and Goedel used the term hemorrhagic thrombocythemia to describe 
a disorder characterized by permanent elevation of a platelet count to more than three times 
normal, hyperplasia of megakaryocytes, and the tendency for venous thrombosis and   spontaneous 
hemorrhage. Over the last 75 years, and particularly in the past 6 years, major progress has been 
made in our understanding of essential thrombocythemia (ET) and its   pathogenesis with the 
identification of the highly prevalent JAK-2 V617F and other mutations. Current   management 
of this condition is based upon historical data and with treatments that have not changed 
  significantly for nearly two decades. This study discusses this and recent progress,   highlighting 
exciting new data with old and new drugs, as well as which patients in particular should be 
evaluated for these new therapies.
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Introduction
Essential thrombocythemia (ET) is the most common of the myeloproliferative 
  neoplasms (MPNs), with an incidence estimated at 1.5–2 individuals per 100,000 
annually.1 The median age at diagnosis is 50–55 years, although the diagnosis is 
increasingly being made in younger adults. In fact, a second peak at about 30 years has 
been noted. The majority of those diagnosed at this age are female, raising important 
management issues in this group at child-bearing age. ET is characterized by a variable 
rate of thrombotic and hemorrhagic complications, and long-term risk of myelofibrotic 
and/or leukemic transformation.2
The optimal management of ET remains controversial, due to the heterogeneity 
of the disorder and limitations – particularly the side effects – of current therapeutic 
modalities. The discovery of JAK-2 V617F mutation, an activating tyrosine kinase 
mutation commonly found in MPNs, ie, polycythemia vera (PV), ET, and primary 
myelofibrosis (PMF), has created intense interest in developing novel agents to target 
JAK-2 in the treatment of MPNs.3 This mutation, located within the autoinhibitory 
pseudokinase domain of JAK2, results in constitutive activation of this key tyrosine 
kinase that is associated with most hemopoietic growth factor receptors. More than 
95% of PV patients carry the mutation, compared to about half of all those with ET 
or PMF, albeit at different levels of allele burden.4 Although the JAK-2 V617F muta-
tion is the most common mutation associated with ET, other mutations also lead to 
constitutive JAK-2 activity, eg, MPLW515L/K mutations in the MPL receptor resides 
on exon 10 account for a further 4% of ET patients.5Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
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This paper reviews the current therapies and their limita-
tions and discusses novel agents as well as future therapeutic 
strategies available in the management of ET.
Achieving a diagnosis
There are a large number of potential causes of thrombocy-
tosis which need to be excluded when making a diagnosis 
of ET. In 1986, the first diagnostic criteria for ET were 
  proposed by the Polycythemia Vera Study Group.6 The 
criteria were most recently modified by the World Health 
  Organization in 2008, in light of the discovery of the JAK2 
V617F   mutation.7 The BCSH have recently proposed a 
modification of  these diagnostic criteria, as shown in Table 1, 
acknowledging difficulties in the recognition of specific 
histological features associated with ET and early primary 
myelofibrosis (PMF).8,9
Who do we currently treat  
and what with?
ET presents in children and adults of all ages. The risks 
associated with the disease as well as potential side effects 
of therapies have led to risk stratification being developed to 
guide treatment philosophy. The aims of current treatment 
are to reduce thrombotic and hemorrhagic complications; 
minimize the risk of transformation to acute myeloid leuke-
mia and post ET myelofibrosis; control symptoms and avoid 
iatrogenic harm due to drug-related toxicity or adverse event. 
It is notable that cure is not a treatment aim; this illustrates 
the limitations of current therapies.
Risk stratification is currently based upon factors known 
to be associated with the risks of thrombosis or hemorrhage. 
The risk factors for hemorrhage are a history of disease-
related hemorrhage or excessive thrombocytosis, while the 
well-established risk factors for thrombotic complications in 
ET are age .60 years and a history of previous thrombosis 
(reviewed in Harrison et al8). Patients with these risk factors 
would probably benefit from cytoreductive therapy and would 
currently be regarded as high-risk patients. As yet, there is 
little international consensus regarding other risk categoriza-
tions, in particular whether there is a true intermediate-risk 
group and how to account for established vascular risk factors 
such as smoking.10
There is an increasing body of evidence that other factors 
should be considered during risk stratification and future 
algorithms. These include leukocytosis; both the presence 
and quantity of the JAK2 V617F mutation; and possibly 
the presence of bone marrow fibrosis. In 1998, Lengfelder 
et al reported a retrospective study of 143 patients, compar-
ing white cell counts at presentation, and noted an elevated 
white cell count was an indicator of poorer outcome.11 More 
recent work suggests that leukocytosis above 15 × 109/L is 
associated with increased thrombotic risk.12 It is clear that 
further work is necessary to establish leukocytosis as a more 
reliable determinant of those at risk of thrombosis. Several 
studies have assessed the impact of the JAK2 V617F mutation 
upon thrombotic risk in ET patients. These studies variably 
identified those patients who were JAK2 V617F-positive 
to have a higher risk of thrombotic complications, a result 
that has been confirmed in a recent meta-analysis.13 Increas-
ing mutant allele quantity also correlated with a higher 
frequency of arterial thrombosis at diagnosis, although the 
evidence for this is limited and few patients with ET have 
substantial allele burdens.4 In an analysis of the MRC PT1 
trial, cohort reticulin grade was also correlated with throm-
bosis.14 In the future, consideration of these factors could 
improve risk stratification.
High-risk patients
Current therapeutic agents for ET are summarized in Table 2 
and response criteria from the European LeukemiaNet in 
Table 3.15 Unfortunately, there are relatively few large-scale 
Table 1 Diagnostic criteria for essential thrombocythemia (eT)37
WHO diagnostic criteria as proposed in 20087
Diagnosis requires meeting all four criteria
1.  Sustained platelet count $450 × 109/L during the work-up period
2.    Bone marrow biopsy specimen showing proliferation mainly of the 
megakaryocytic lineage with increased numbers of enlarged, mature 
megakaryocytes; no significant increase or left-shift of neutrophil 
granulopoiesis or erythropoiesis
3.    Not meeting wHO criteria for Pv, PMF, CML, MDS, or other 
myeloid neoplasm
4.  Presence of an acquired pathogenic mutation ( JAK2 or MPL)
Modified WHO criteria as proposed by BCSH8
Diagnostic criterion To make a diagnosis of ET requires 
either A1+A2 or A1+A3-A5
A1 Sustained platelet count .450 × 109/L
A2 Presence of an acquired pathogenic 
mutation ( JAK2 or MPL)
A3 No other myeloid malignancy, especially 
Pv, PMF, CML, or MDS
A4 No reactive cause for thrombocytosis and 
normal iron stores
A5 Bone marrow aspirate and trephine 
histology showing increased 
megakaryocytes number with prominent 
large hyperlobated forms; reticulin is 
generally not increased ($2 on a 0–4 scale)
Abbreviations:  BCSH,  The  British  Committee  for  Standards  in  Haematology; 
CML, chronic myeloid leukemia; MDS, myelodysplastic syndrome; PMF, primary 
myelofibrosis; PV, polycythemia vera; WHO, World Health Organization.Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
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Table 2 Currently available therapies in management of essential thrombocythemia (eT)
Agent Mode of action Adverse effects Ability to moderate 
AML or post-ET MF
Effects upon  
malignant clone
Aspirin COX inhibition Hemorrhage, peptic ulceration No None
Hydroxycarbamide Ribonucleotide reductase  
inhibitor
Gi symptoms, cytopenias, 
mucocutaneous ulceration,  
pigmentation
Potentially leukemogenic.  
May reduce post eT MF
Probably none
Anagrelide imidazo-quinazinolone Headache, palpitations, fluid  
retention
increased post eT MF  
compared with 
hydroxycarbamide
None
interferon α Naturally occurring  
cytokine
Gi symptoms, depression,  
flu-like symptoms, thyroid disease
Unknown May reduce
Busulfan Alkylating agent metabolic  
competitor of pyrimidine  
bases
Gi symptoms, liver dysfunction,  
pulmonary fibrosis, seizures
Leukemogenic  
May affect post eT MF
Probably none
Pipobroman Alkylating agent Pancytopenia Leukemogenic 
May affect post  eT MF
Probably none
Phosphorus 32 irradiation Pancytopenia Leukemogenic  
May affect post eT MF
Probably none
Abbreviations: AML, acute myeloid leukemia; ET MF, essential thrombocythemia myelofibrosis; GI, gastrointestinal.
Table 3 european LeukemiaNet criteria for response in eT
Criteria for clinical response in ET
Complete response 
– Platelet count #400 × 109/L AND 
– No disease-related symptoms* AND 
– Normal spleen size on imaging AND 
– wBC #10 × 109/L
Partial response 
– in patients who do not meet criteria for complete response 
– Platelet count # 600 × 109/L OR .50% reduction from baseline
No response 
– Any response that does not satisfy partial criteria
Criteria for molecular response in ET
Complete response 
–   Reduction of any specific molecular abnormality to undetectable  
levels
Partial response* 
–   A reduction of .50% from baseline value in patients with #50% 
mutant allele burden at baseline
OR
–   Reduction of .25% from baseline value in patients with $50% mutant 
allele burden at baseline
No response 
– Any response that does not satisfy either complete or partial response
Criteria for histological response in ET
Histological remission 
– Absence of megakaryocyte hyperplasia
Note: *Applies only to patients with a baseline value of mutant allele burden .10%.
Abbreviation: eT, essential thrombocythemia.
randomized controlled studies in ET to inform the use of 
these agents. These are summarized in Table 4 and include 
the ‘Bergamo study’,16 MRC PT-1 high risk arm,17 and the 
Anahydret trial.18 The current agent of choice is hydroxy-
carbamide (HC) but there are concerns over the increased 
risk of leukemic transformation in patients treated with this 
agent. Clinical studies attempting to address this issue have 
returned conflicting results, often confounded by factors such 
as small numbers, the use of multiple therapies, lack of proper 
controls, retrospective data collection, and relatively short 
follow-up. Another confounding factor is that transformation 
may occur anyway, in the absence of cytoreductive therapy. 
The most recent data from the Swedish cancer registry sug-
gests no excess risk of leukemia19 and contradicts long-term 
follow-up of French PV patients,20 suggesting appreciable 
risk, albeit in a related disease with no untreated controls. 
For these reasons anagrelide and interferon are often con-
sidered for young patients, and interferon may well emerge 
as a treatment of choice (as discussed below) but this will 
require further evaluation.21
An area of concern, where good-quality evidence is 
currently lacking, is the management of those patients who 
are refractory or resistant to HC. This will be discussed in 
detail as this group of patients has limited therapeutic options 
and would likely benefit from future therapies. Criteria 
for resistance and intolerance have been developed by the 
European LeukemiaNet,22 as seen in Table 5. Options for 
management in the face of HC resistance would include 
adjusting therapeutic targets (for example to a platelet count 
of 600 × 109/L) or switching to an alternative agent either 
alone or in combination. In this regard, and for the manage-
ment of intolerance, it is important to consider that when 
HC is used with or succeeded by agents with leukemogenic 
potential, such as busulfan, this will significantly potentiate 
the leukemogenicity of either agent alone.23 For this reason Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
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non-leukemogenic agents such as interferon-α or anagrelide 
are considered more appropriate in this setting.
Low- and intermediate-risk patients
Two ongoing randomized trials will further inform the man-
agement of ET. The first is the National Cancer Research 
Institute study for intermediate-risk patients (defined here 
as age 40–60 years with no high-risk features). This is a ran-
domized comparison of HC plus aspirin with aspirin alone. 
It is expected to report in 2012. Until the results of this study 
are known, treatment guidelines for this intermediate-risk 
group of patients remain poorly evidence based. The National 
  Cancer Research Institute study for low-risk patients (defined 
as age ,40 years with no high-risk features), is also open and 
is an observational study with recommended management of 
aspirin only.   Support for this strategy of aspirin for the majority 
of patients with ET in the absence of clear contraindications 
comes from the ECLAP study, a randomized comparison of 
aspirin with no antiplatelet therapy in PV patients at low or 
intermediate risk of vascular events.24 This demonstrated a 
significantly reduced risk of vascular events in patients ran-
domized to receive aspirin, and the benefits of aspirin came at 
no increased risk of major hemorrhage. A recent retrospective 
review of 300 low-risk ET patients in Spanish centers where 
antiplatelet agents (mostly aspirin) were given at the discretion 
of investigators suggested that aspirin protected patients with 
cardiovascular risk factors against arterial events and those 
with the JAK2 V617F mutation against venous events. There 
is, however, an underlying risk of hemorrhage for those patients 
with platelet counts over 1000 × 109/L.25 This study suggests 
in the future that recommendations for aspirin in ET should 
be reviewed. However, as it also recorded a death from PE in 
one patient, it highlights that low risk does not equate to no 
risk due to disease.
Limitations of current treatments 
and treatment strategies
Current therapies and risk stratification for ET as discussed 
above have changed little over the past two decades, reflect-
ing a lack of understanding regarding pathogenesis of the 
disease that could then be used to design newer therapies. The 
clinical heterogeneity of the condition and its low prevalence 
has also hampered progress. The description of the JAK2 
V617F mutation and others in these patients has reinvigorated 
this field and resulted in significant advances.
Table 4 Comparison of pivotal studies in essential thrombocythemia
Anahydret trial PT-1 trial Bergamo trial
Diagnosis wHO criteria (2001) 
Central review of histology
PvSG criteria 
Diagnosis by treating physician
Cortelazzo S et al28
Patients High-risk  
Treatment naive
High-risk 
Treated or untreated
High-risk 
Treated or untreated
Median age (years): anagrelide/HC/ 
control
58/56/– 61/62/– –/56/58
Patient numbers 122 (ANAG) 
136 (HC)
405 (ANAG/aspirin) 
404 (HC/aspirin)
67 (HC) 
69 (control)
Follow-up 
(patient years)
539 2653 257
Total events
Arterial thrombosis 10 54 2/11
venous thrombosis 7 17 0/3
Hemorrhage 6 30 7
Transformation to MF 0 21 ?
Conclusion ANAG non-inferior HC/aspirin superior to ANAG/aspirin HC superior to control, 
aspirin not controlled
Abbreviations: ANAG, anagrelide; HC, hydroxycarbamide; PvSG, Polycythaemia vera Study Group; wHO, world Health Organization.
Table 5 european LeukemiaNet criteria for resistance or intolerance 
to hydroxycarbamide in essential thrombocythaemia eT
Any ONE of
Resistance
1.    Platelet count .600 × 109/L after 3 months of at least 2 g/day of 
hydroxycarbamide (2.5 g/day in patients with a body weight .80 kg), 
OR
2.    Platelet count .400 × 109/L and wBC count ,2.5 × 109/L at any 
dose of hydroxycarbamide, OR
3.    Platelet count .400 × 109/L and hemoglobin ,10 g/dL at any dose  
of hydroxycarbamide 
OR
intolerance
4.    Presence of leg ulcers or other unacceptable mucocutaneous 
manifestations at any dose of hydroxycarbamide, OR
5.  Hydroxycarbamide-related feverJournal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
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Current treatments as discussed above include active 
monitoring only and low-dose aspirin alone or in combina-
tion with cytoreductive therapies. Therapies are generally 
used alone rather than in combination, which is an unusual 
feature in hematological malignancies. None of these current 
strategies addresses or directly targets either the malignant 
clone, evolution of the disease, or symptoms suffered by 
patients that affect quality of life. With regard to symptoms, an 
international collaboration using a specifically developed and 
validated quality of life tool (myeloproliferative neoplasms-
symptom assessment form MPN-SAF)26 demonstrates that 
many patients have burdensome symptoms, such as fatigue 
and pruritis, that significantly impact upon their lives. Both 
malignant clone and symptoms targets are relevant in evalu-
ating newer treatments and have indeed been incorporated 
into treatment response criteria, which have been established 
through the European LeukemiaNet and are summarized in 
Table 3.15 There are also difficulties in determining clonal remis-
sion and challenges in establishing highly sensitive assays for 
the JAK2 V617F mutation that yield reproducible results at 
a highly sensitive level, but work is ongoing to achieve this.
A difficulty in assessing treatments and their ability to 
reduce or slow secondary events in ET like leukemia or 
myelofibrosis, is that such events are an infrequent occur-
rence in common clinical practice. The group of patients 
who are HC refractory or resistant, however, are a good target 
for evaluating newer therapies in this regard. For example, 
  Spanish investigators have retrospectively evaluated   European 
LeukemiaNet criteria for clinical response and then resistance/
intolerance to HC in 166 ET patients treated with HC for a 
median of 4.5 years.27 Overall, 134 patients achieved a com-
plete clinicohematological response and 25 a partial response. 
Of note, patients achieving a complete response (CR), even if 
sustained during the entire follow-up, did not benefit from a 
lower incidence of thrombosis or an improved survival, sug-
gesting that clinicohematological response may not be the best 
target for novel therapies. Regarding resistance or intolerance, 
33 patients met at least one of the criteria defining resistance 
(n = 15) or intolerance (n = 21) to HC. Fifteen cases developed 
anemia with thrombocytosis, which was associated with a high 
incidence of myelofibrosis and death from any cause. Other 
definitions of resistance were less useful. Future trials should 
be designed with these important results in mind.
Novel agents
Simple statins
The impact of conventional risk factors for   atherosclerosis, 
including hyperlipidemia and hypertension, has been assessed 
in MPN with variable results. Limited work, however, has 
been specifically performed in ET.29 Recent recommenda-
tions for the management of atherosclerosis suggest that this 
patient group may benefit from aggressive risk management 
with the use of antihypertensives and a statin, where appro-
priate. An issue and concern is when the statin or alternative 
agent might be appropriate and what the treatment target 
should be. There is a strong rationale for the use of statins 
in these disorders, bearing in mind the pleomorphic effects 
of statins with regard to apoptosis, angiogenesis and perhaps 
the most recent being the observation that JAK2 is present 
in ‘lipid rafts’ in the cell membrane.30 A randomized study 
in this setting to address the utility of agents such as statins 
is unlikely but mechanistic support from well-designed cell 
line or animal model-based experiments, followed by obser-
vational studies, could be of benefit.
PeGylated interferon alpha (iNFα)
Recently, two Phase II studies have evaluated the role of the 
PEGylated interferon alpha 2a isoform of IFN (Pegasys, 
Roche); their results are also supported by cohorts of patients 
reported in abstract form. The first, called PVN1, was a 
multicenter Phase II trial involving only PV patients but still 
of relevance. Here Kiladjian and coworkers prospectively 
evaluated clinical, hematological, and molecular response.31 
At 12 months, all 37 evaluable patients had hematologic 
response, including 94.6% CRs. Only three patients (8%) had 
stopped treatment. After the first year, 35 patients remained 
in hematologic CR, including five who had stopped Pega-
sys. Sequential samples for V617F monitoring, available 
in 29 patients, showed a percentage V617F decrease in 26 
(89.6%). Median percentage V617F decreased from 45% to 
22.5%, 17.5%, 5%, and 3% after 12, 18, 24, and 36 months, 
respectively. Molecular CR (JAK2  V617F undetectable) was 
achieved in seven patients, lasting from 6 to 18 months, and 
persisted after Pegasys discontinuation in five patients. No 
vascular event was recorded. The results confirm the hypoth-
esis that IFN-α preferentially targets the malignant clone in 
PV and show that JAK2  V617F allele burden may be useful in 
monitoring minimal residual disease in PV patients. However, 
in a recent update, this group did show that whilst the JAK2 
V617F clone was reduced by Pegasys, the TET-2 mutant 
clones were apparently not affected.32
The second study was conducted by the MD   Anderson 
group and included both PV (n = 40) and ET patients 
(n = 39).33 Here the median time that had elapsed from 
diagnosis was longer, and these patients had previously 
received at least one other cytoreductive drug, therefore Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
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  representing a different clinical and biological cohort. Despite 
this, excellent hematological response rates were observed: 
81%   (including 78% CR), and 92% (including 86% CR) in 
PV and ET, respectively. Major molecular responses were 
achieved in 30% and 13% of PV and ET patients, respectively, 
with 13% of complete molecular responses in both diseases. 
Tolerance was also better than reported with other forms of 
IFN since only 10% of treatment discontinuation was due to 
Pegasys toxicity. No patients suffered grade 4 toxicity, and 
grade 3 toxicities were reported in a small number of patients 
only and only in the following categories: pain, fatigue, 
dyspnea, and pruritis.
The studies of Pegasys in PV and ET described above 
both report high levels of hematologic complete response 
rates; good tolerance of the drug particularly when started 
at low dose; and most significantly a clear selective effect 
on the disease clone in a significant proportion of patients, 
including complete molecular responses. This data has also 
been reported in abstract form for groups of patients man-
aged outside of the context of a clinical trial.34 This data 
suggests that Pegasys may be effective when other therapies 
have failed or not been tolerated and that it may challenge 
the position of HC as a first-line therapy. However this will 
require large randomized trials with comprehensive evalua-
tion for long-term side-effects as the side-effect profile for 
interferon is more adverse than that for HC and there is little 
evidence to support the contention that Pegasys (or indeed 
other PEGylated interferons) are better tolerated than con-
ventional interferon, especially in a disease that (unlike the 
hepatitis field) requires long-term therapy. Two such trials 
are currently being launched internationally: a Phase III 
randomized study of HC vs Pegasys in newly diagnosed 
high-risk ET and PV and a Phase II study of Pegasys in HC 
resistant or refractory patients to include a cohort of patients 
with abdominal vein thrombosis.
JAK inhibitors
A significant number of JAK inhibitors are now at varying 
stages of clinical evaluation with most data available for 
patients with myelofibrosis.35 Most of these agents are well 
tolerated and have a clinically measurable benefit for these 
patients, particularly in reducing symptomatic splenomegaly 
and constitutional symptoms such as pruritis or fatigue. Two 
large Phase III trials in myelofibrosis have recently been 
completed confirming the benefit of these agents in reducing 
splenomegaly and controlling symptoms when compared to 
placebo or physician choice of standard therapies.36,37 As yet, 
there is no conclusive evidence that these agents either 
  significantly reduce the JAK2 V617F mutant allele burden 
or alter the natural history of the disease.
There is, however, emerging data supporting the ability 
of JAK inhibitors to control both myeloproliferation and 
symptoms in patients with PV and ET. In these disorders, 
however, an ability to prevent thrombosis, affect the risk of 
transformation to post-ET or post-PV MF or indeed leukemia 
is also desirable.
Moliterno and colleagues treated 39 patients (12 ET, 
27 PV), all had high-risk disease and prior therapies, with 
CEP 701 (Cephalon®).38 However, marked gastrointestinal 
side effects occurred and whilst there were responses in 
splenomegaly, pruritis, and phlebotomy requirements (after 
6 months), treatment was not associated with a reduction in 
either leukocytosis or thrombosis, as five thrombotic events 
occurred on treatment.
In the study using INC18424 (now termed Ruxolitinib®) 
in 39 ET and 34 PV patients, there were similar rates 
of reduction of splenomegaly and symptom scores. All 
patients had leukocyte counts below 10 × 109/L and 41% 
achieved a CR with platelets less than 400 × 109/L and no 
thrombotic events have been reported.39 Specifically with 
regard to ET, 49% achieved normal platelet counts and 
79% achieved ,600 × 109/L or a $50% reduction as of last 
follow-up visit. Thirteen of 14 subjects with baseline platelet 
counts .1000 × 109/L have achieved a .50% reduction. 
Importantly this study demonstrated marked and sustained 
benefit of this agent upon quality of life concerns, in par-
ticular pruritus but also fatigue. Ruxolitinib therapy was 
recently demonstrated in two Phase III trials to be of benefit 
in PMF patients when compared to placebo or best available 
therapy (ie, standard of care) in reduction of spleen volume 
and quality of life.36,37 Data with regard to survival advantage 
or transformation to leukemia is awaited with interest. This 
agent appears to have only modest benefit in targeting the 
malignant clone specifically. In PV patients refractory or 
intolerant of HC a trial termed ‘RESPONSE’ is currently 
underway to assess the utility of Ruxolitinib® compared 
with best available therapy (http://www.responsetrial.com; 
or http://clinicaltrials.gov/ct2/show/NCT01243944).
Further results from larger studies with longer follow-up 
are required for JAK inhibitor therapy, but it appears that 
these drugs have the relatively unique contribution of 
addressing the patient symptoms. An initial impression is 
that in order to attain clonal response or complete remission 
it is likely to be necessary to combine these agents with 
another therapeutic modality. PEGylated interferon is an 
obvious choice, although to be able to escalate dose whilst Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
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ameliorating the consequent anemia or thrombocytopenia, 
agents such as erythropoietin may be required.
Histone deacetylase inhibitors
Interest in histone deacetylase inhibitors such as panobin-
ostat, vorniostat, and givinostat in patients with ET and PV 
is growing as a single therapy or in combination with other 
therapies. Histone-deacetylases (HDACs) are enzymes 
involved in the remodeling of chromatin, and have a key role 
in the epigenetic regulation of gene expression. In addition, 
the activity of non-histone proteins can be regulated through 
HDAC-mediated hypoacetylation. Altered expression of 
HDAC has been reported in MPN patients that, in addition 
to their pleiotropic actions, makes these drugs an interesting 
option for clinical trials in ET. In recent years, inhibition of 
HDACs has emerged as a potential strategy to reverse aber-
rant epigenetic changes associated with cancer.40   Givinostat® 
(ITF2357; Italfarmaco S.p.A., Cinisello Balsamo, Italy) 
is a synthetic class I and II HDAC inhibitor with potent 
anti-proliferative and pro-apoptotic activity against several 
hematological malignancies.41 In addition to these anti-tumor 
features, preclinical studies of Givinostat also showed that 
it could inhibit the production/release of several cytokines, 
including tumor necrosis factor-α (TNF-α), interleukin (IL)-
1b, IL-6, IL-12, c-interferon (IFNc), and vascular endothelial 
growth factor (VEGF) by neoplastic as well as endothelial 
and mesenchymal cells.42
Based on these properties, Givinostat was evaluated in 
the treatment of JAK2 V617F positive PV , ET, and PMF.43 
Givinostat was given orally for 24 weeks at a starting dose 
of 50 mg twice daily with a median treatment duration of 
20 weeks. Reasons for treatment discontinuation were dis-
ease progression (n = 6), grade 2 thrombocytopenia (n = 1), 
  psychiatric symptoms (n = 1), and withdrawn consent (n = 2). 
A dose reduction was applied in ten patients while a temporary 
interruption occurred in 15. Among 13 PV/ET patients, one 
complete, six partial, and four no responses were documented 
at study end. Two patients went off-study, prematurely, and 
concomitant HC was required in four patients. Strikingly, 
pruritus disappeared in most patients and reduction of sple-
nomegaly was observed in 75% of PV/ET patients. Reverse 
transcription polymerase chain reaction identified a modest 
trend to reduction of the JAK2  V617F allele burden.
A notable feature of HDAC is that they do not appear to 
be as well tolerated as conventional ET therapy such as HC. 
However, their striking effect upon symptoms and potentially 
allele burden means they would perhaps be re-evaluated 
at either a different dose or perhaps in combination with 
other agents. Rambaldi et al describes co-administration 
with HC43 and in a cell-line model, Wang and colleagues30 
describe that combined treatment with panobinostat and 
the JAK2 inhibitor TG101209 attenuates JAK2 V617F 
levels and signaling and exerts synergistic cytotoxic effects 
against human myeloproliferative neoplastic cells. They 
demonstrated that panobinostat treatment depletes the auto-
phosphorylation, expression, and downstream signaling of 
JAK2 V617F and disrupted the chaperone association of 
JAK2 V617F with heat shock protein 90, thus promoting 
proteasomal degradation of JAK2 V617F. Combined treat-
ment with panobinostat and TG101209 further depleted 
JAK/STAT signaling and synergistically induced apoptosis 
of JAK2  V617F expressing cell lines.30 These observations 
provide a rationale for cotreatment with HDAC, heat shock 
protein 90, as well as JAK inhibitors.
Conclusions
The management of ET has previously been problematic from 
the perspective of achieving a timely certain diagnosis and the 
absence of robust evidence-based clinical management 
guidelines. This is a relatively rare condition viewed by many 
as indolent. Until recently there have been no major advances 
in our understanding of disease biology or pathogenesis to 
inform treatment options and strategies. Recent advances in 
our understanding of the molecular pathogenesis of these 
disorders and data from clinical trials has improved this. 
Evidence is now growing to support a reconsideration of the 
classification of these disorders from essentially those based 
upon clinical and morphological descriptions to   molecular- 
and clinical-based classification based upon prospective 
correlative analyses from large numbers of patients. There 
have been further refinements and better agreement upon 
what the indications for cytoreductive therapy are. Yet we still 
lack agents which achieve our therapeutic goals and robust 
data about long-term safety (particularly   leukemogenicity) 
of commonly used agents such as HC. Confusion also con-
tinues regarding who should receive antiplatelet agents, most 
commonly low-dose aspirin, and indeed when treatment with 
agents such as statins may be required or beneficial.
We are gaining a better understanding of which patients 
are in most need of treatment and are perhaps beginning to 
assess true remission as a treatment target. To this end, interest 
in interferons has been rejuvenated with data suggesting that 
PEGylated interferons may induce high levels of clinical and 
hematologic remission and also in some patients a molecular 
complete response. A robust clinical study in newly diag-
nosed high-risk ET is required to evaluate the comparison Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
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between HC and Pegasys. Patients with HC intolerance or 
resistance provide an important highly relevant group to study 
more experimental agents, such as JAK2 inhibitors.
The success of imatinib in chronic myeloid leukemia as 
yet has not been reproduced using JAK2 inhibitors in ET, 
illustrating important differences in the pathobiology of the 
JAK2 V617F mutation and BCR/ABL translocation. These 
newer agents deliver treatment against symptoms producing 
a response not gained with other agents, and these benefits 
are both unique and important for patients. Additional novel 
therapeutics such as HDAC inhibitors either alone or in 
combination are also currently being explored.
Lastly, this paper also discussed the relevance of treatment 
targets and strategies including whether we should now be 
switching our strategy to try to deliver a complete response 
or cure for all patients. This seems a goal for the future but a 
more pressing one is the need to identify robustly the toxicity 
of current treatments, even including aspirin and HC, and to 
identify which treatments address patient needs with regard 
to quality of life.
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